X
[{"orgOrder":0,"company":"RayzeBio","sponsor":"venBio Partners","pharmaFlowCategory":"D","amount":"$45.0 million","upfrontCash":"Undisclosed","newsHeadline":"RayzeBio Launches with $45 Million Series A to Advance Portfolio of Targeted Radiopharmaceuticals for Cancer Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"RayzeBio","sponsor":"PeptiDream","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"RayzeBio Propels Forward with $418 Million Raised Since Inception to Advance Targeted Radiopharmaceuticals for Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RayzeBio Advances RYZ101, a Targeted Radiopharmaceutical Delivering Actinium-225, into Clinical Development for Two Cancer Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RayzeBio Announces Issuance of Two Patents for RYZ101 (225Ac-DOTATATE)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RayzeBio Completes Phase 1b Enrollment in ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RayzeBio Nominates Glypican-3 (GPC3) Targeted Radiopharmaceutical Therapy Drug Candidate for Treatment of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RayzeBio Announces First Patient Dosed in Phase 3 ACTION-1 Study, Evaluating RYZ101 (Actinium-225 DOTATATE) in Neuroendocrine Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RayzeBio Announces Initial Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"RayzeBio","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","amount":"$358.0 million","upfrontCash":"Undisclosed","newsHeadline":"RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters\u2019 Option to Purchase Additional Shares","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$4,100.0 million","upfrontCash":"$4,100.0 million","newsHeadline":"Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"RayzeBio","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$4.1 million","upfrontCash":"$4.1 million","newsHeadline":"Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by RayzeBio
Filters
Companies By Therapeutic Area
Details:
Through the acquisition, Bristol includes RYZ101 (actinium-225 dotatate) targeting somatostatin receptor 2. It is currently being evaluated in patients for the treatment of SSTR-positive Gastroenteropancreatic Neuroendocrine Tumors.
Lead Product(s):
Actinium-225 Dotatate
Therapeutic Area: Oncology
Product Name: RYZ101
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Bristol Myers Squibb
Deal Size: $4.1 million
Upfront Cash: $4.1 million
Deal Type: Acquisition
February 26, 2024
Details:
By acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform, BMS will establish its presence in one of the most promising and fastest-growing new modalities for solid tumors, by delivering radioactive payloads to cancer cells in a targeted manner.
Lead Product(s):
Actinium-225 Dotatate
Therapeutic Area: Oncology
Product Name: RYZ101
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Bristol Myers Squibb
Deal Size: $4,100.0 million
Upfront Cash: $4,100.0 million
Deal Type: Acquisition
December 26, 2023
Details:
RYZ101 (Actinium-225 DOTATATE) is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors.
Lead Product(s):
Actinium-225 Dotatate
Therapeutic Area: Oncology
Product Name: RYZ101
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 24, 2023
Details:
The proceeds will advance clinical development of RYZ101 (actinium-225 dotatate) in company's Phase 3 trial in GEP-NETs, RYZ101 through Phase 1b efficacy data in ES-SCLC and IND enabling activities and clinical development of RYZ801 and RYZ811 in HCC through Phase 1.
Lead Product(s):
Actinium-225 Dotatate
Therapeutic Area: Oncology
Product Name: RYZ101
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
J.P. Morgan
Deal Size: $358.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
September 19, 2023
Details:
The proceeds will advance IND enabling activities and clinical development of RYZ801, a novel proprietary peptide which targets GPC3 for delivery of Ac225, and RYZ811 in HCC through Phase 1b safety data and the development of RYZ101 for GEP-NETs and extensive-stage SCLC.
Lead Product(s):
RYZ801,Actinium-225
Therapeutic Area: Oncology
Product Name: RYZ801
Highest Development Status: IND Enabling
Product Type: Peptide
Partner/Sponsor/Collaborator:
J.P. Morgan
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Public Offering
August 25, 2023
Details:
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors.
Lead Product(s):
Actinium-225 Dotatate
Therapeutic Area: Oncology
Product Name: RYZ101
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 31, 2023
Details:
Novel peptide drug candidate against GPC3 was nominated as GPC3 is selectively overexpressed in hepatocellular carcinoma and not expressed in normal liver and other tissues, making it the potential targeted cancer therapy.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Peptide
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 21, 2023
Details:
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing SSTR2.
Lead Product(s):
Actinium-225
Therapeutic Area: Oncology
Product Name: RYZ101
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 20, 2023
Details:
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2).
Lead Product(s):
RYZ101
Therapeutic Area: Oncology
Product Name: RYZ101
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 04, 2023
Details:
RYZ101 is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), to tumors expressing the somatostatin receptor type 2 (SSTR2).
Lead Product(s):
RYZ101
Therapeutic Area: Oncology
Product Name: RYZ101
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Viking Global Investors
Deal Size: $160.0 million
Upfront Cash: Undisclosed
Deal Type: Series D Financing
September 13, 2022